The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.

[1]  J. Hoofnagle,et al.  Optimal therapy of hepatitis C , 2002, Hepatology.

[2]  P. Couzigou,et al.  Combination of ribavirin and interferon‐alfa surpasses high doses of interferon‐alfa alone in patients with genotype‐1b–related chronic hepatitis C , 2000, Hepatology.

[3]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[4]  N. Hayashi,et al.  Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus: a multicenter controlled study , 2000 .

[5]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[6]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[7]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[8]  Aril Frydén,et al.  Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.

[9]  N. Hayashi,et al.  Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. , 1997, Gastroenterology.

[10]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[11]  Ding‐Shinn Chen,et al.  Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. , 1996, Gastroenterology.

[12]  N. Hayashi,et al.  Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C , 1995 .

[13]  N. Hayashi,et al.  Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial , 1995, Hepatology.

[14]  N. Hayashi,et al.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. , 1995, Journal of hepatology.

[15]  J. Garson,et al.  A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. , 1994, Gastroenterology.

[16]  S. Yagi,et al.  Significance of specific antibody assay for genotyping of hepatitis C virus , 1994, Hepatology.

[17]  T. Ishikawa,et al.  A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. , 1993, Gastroenterology.

[18]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[19]  N. Hayashi,et al.  Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. , 1993, Gastroenterology.

[20]  Eugene R. Schiff,et al.  Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa , 1989 .

[21]  S. Banks,et al.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.

[22]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.